Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Ebola Vaccine Found to Protect Monkeys

By Biotechdaily staff writers
Posted on 13 Aug 2003
A study has shown that a single dose of a fast-acting experimental vaccine against the Ebola virus was able to protect monkeys from the virus after only one month. More...
The study was reported in the August 7, 2003, issue of Nature.

Researchers had been pursuing a "prime-boost” vaccine strategy against a variety of infectious diseases. Prime-boost is a two-part process that comprises an injection of noninfectious genetic material from the disease-causing microbe to prime the immune system to respond, and several weeks later, an injection of attenuated carrier viruses containing key genes from the microbe to substantially boost the immune response. The boost produces a weaker immune response but is quicker. Since time is critical when fighting Ebola, they decided to test whether the boost's fast response alone was strong enough to protect against the virus.

Eight monkeys were immunized with a single injection, consisting of attenuated carrier viruses containing genes for important Ebola antiens. The monkeys were then injected with an Ebola virus strain. The single vaccine injection completely protected all eight animals against Ebola infection, even those who received high doses of the virus. The study was conducted by scientists at the National Institute of Allergy and Infectious Diseases (NIAID) and the United States Army Medical Research Institute of Infectious Diseases at Fort Detrick, MD, USA).

"This research has enormous public health implications not only because it might be used to limit the spread of Ebola virus but also because this vaccine strategy may be applied to other highly lethal viruses, such as the Marburg and Lassa fever viruses and the SARS Coronavirus, that cause acute disease outbreaks and require a rapid response,” said Anthony S. Fauci, M.D., director of NIAID.




Related Links:
National Institute of Allergy and Infectious Diseases

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.